Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...
Bone morphogenetic proteins (BMPs) are growth factors that regulate the size of intestinal crypts. This study shows that ...
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating ...
Some cells, such as immune cells, are highly mobile—they constantly remodel their shape, migrate toward a wound that needs to ...
News Medical on MSN
How to Keep Cells Out of Limbo and Prevent Lung Scarring
Scientists at UCSF identified a key cellular switch that plays a large role in pulmonary fibrosis, and found a way of ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...
In CF, those with 2 ETI-responsive CTFR variants (vs 1 variant) are twice as likely to have sweat chloride concentrations on ETI within normal range.
Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral immune tolerance.
Gilead Sciences, Inc. and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 ...
The US FDA has granted breakthrough therapy designation (BTD) to the bifunctional antibody ficerafusp alfa (BCA101) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback